Preliminary Efficacy Analysis of "C" Single Flap Plasty Reconstruction After Laparoscopic Proximal Gastrectomy

Launched by DAORONG WANG · Dec 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new surgical method called "C" Single Flap Plasty Reconstruction for patients with early-stage gastric cancer, specifically in the upper part of the stomach. The goal is to see if this new approach can effectively treat cancer while also helping to prevent issues like reflux, which can happen after surgery. The trial will involve patients aged 18 to 80 who have been diagnosed with certain types of stomach cancer and meet specific health criteria.

To be part of this study, participants must not have any distant spread of cancer and should not have specific health conditions that could complicate surgery. If eligible, patients can expect to undergo the "C" reconstruction procedure along with standard care for their cancer. Before joining, patients and their families will need to provide consent, ensuring they understand what the study involves. This trial represents an important step in finding better surgical options for patients with gastric cancer, aiming to improve both treatment outcomes and quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age between 18-80 years old, male or female;
• • 2. Pathological diagnosis of preoperative endoscopic biopsy: the tumor is located in the upper 1/3 of the stomach (including the esophagogastric junction), and the clinical staging of gastric cancer： Ia and Ib (T1N0M0, T1N1M0, and T2N0M0) according to the eighth edition of the AJCC ;
• • 3. No distant metastasis was observed on preoperative chest radiograph, abdominal ultrasound, or upper abdominal CT;
• • 4. ASA grade 1-3;
• • 5. Patients without contraindications to surgery;
• • 6. Patients and their families voluntarily signed the informed consent form and participated in the study;
• Exclusion Criteria:
• • 1. Patients diagnosed with primary tumors or distant metastasis;
• • 2. Patients whose tumor is located in the greater curvature side of the stomach;
• • 3. Patients with coagulation dysfunction that could not be corrected;
• • 4. Patients who were diagnosed with viral hepatitis and cirrhosis;
• • 5. Patients who were diagnosed with diabetes mellitus, uncontrolled or controlled with insulin;
• • 6. Patients with organ failure such as heart, lung, liver, brain, and kidney failure;
• • 7. Patients with ascites or cachexia preoperatively in poor general conditions;
• • 8. Patients diagnosed with immunodeficiency, immunosuppression, or autoimmune diseases (such as allogeneic bone marrow transplant, immunosuppressive drugs, SLE, etc.).
• • 9. Patients refusing to sign the informed consent of the study;